Cargando…

A case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib

INTRODUCTION: We report a case of renal cell carcinoma with vena cava thrombus showing a marked reduction with presurgical avelumab plus axitinib, facilitating nephrectomy with thrombectomy. CASE PRESENTATION: A 50‐year‐old man was taken to emergent care unit due to spontaneous renal rupture and was...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Issei, Kijima, Toshiki, Takada‐Owada, Atsuko, Nakamura, Gaku, Uematsu, Toshitaka, Sakamoto, Kazumasa, Nishihara, Daisaku, Ishida, Kazuyuki, Kamai, Takao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560442/
https://www.ncbi.nlm.nih.gov/pubmed/34755071
http://dx.doi.org/10.1002/iju5.12362
Descripción
Sumario:INTRODUCTION: We report a case of renal cell carcinoma with vena cava thrombus showing a marked reduction with presurgical avelumab plus axitinib, facilitating nephrectomy with thrombectomy. CASE PRESENTATION: A 50‐year‐old man was taken to emergent care unit due to spontaneous renal rupture and was diagnosed to have left‐sided renal cell carcinoma with level IV tumor thrombus. After hemostasis was obtained via transcatheter arterial embolization, avelumab plus axitinib was introduced because upfront surgery was deemed unfeasible due to poor performance status and possible retroperitoneal tumor dissemination. After four treatment cycles, thrombus was reduced to level II, and nephrectomy with thrombectomy was performed. Histological analyses revealed massive CD8(+) T cell infiltration in the thrombus, suggesting immunotherapy efficacy. He has remained recurrence‐free without any additional treatment for eight months. CONCLUSION: For locally advanced renal cell carcinoma with vena cava thrombus, presurgical combination therapy with avelumab plus axitinib could be an option to facilitate curative surgery.